BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases
PALO ALTO, CA – July 21, 2022 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced a new collaboration with Baylor College of Medicine to identify and translate cutting-edge research into potential therapies for patients with genetic diseases.
“In these challenging times we believe it is more important than ever to be a stalwart partner to academic institutions working to serve patient populations big and small. We look forward to developing a close partnership with scientists at Baylor College of Medicine, which is known for its productive research engine, in the hope of translating innovations into meaningful medicines for patients with unmet medical needs,” said Neil Kumar, Ph.D., BridgeBio founder and CEO.
Baylor College of Medicine’s unique approach to therapeutic development for genetic diseases and precision oncology integrates basic, translational and clinical sciences. Through this collaboration, BridgeBio will work with Baylor College of Medicine to identify and translate promising innovations into potential therapies for patients with genetically driven diseases.
“Together with BridgeBio’s drug development team, we are optimistic that our interdisciplinary team of scientists and physicians will be able to develop new therapeutics for patients in need and further our mission to identify and develop drugs for a wide variety of diseases,” said Joseph Petrosino, Ph.D., chief scientific innovation officer and chair and professor of molecular virology & microbiology at Baylor.
A core part of BridgeBio’s efforts to help patients is the identification of new discoveries in academia. Through its academic collaborations, BridgeBio seeks to revolutionize the relationships between the drug development industry and biomedical researchers by moving away from one-off interactions in favor of engaging and creative partnerships. For a list of some of BridgeBio’s academic partners, please visit Our Partners page.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebiodev.wpengine.com and follow us on LinkedIn and Twitter.
BridgeBio Pharma, Inc. Forward-Looking Statements
This press release contains forward-looking statements.
Statements we make in this press release may include statements
that are not historical facts and are considered forward-looking
within the meaning of Section 27A of the Securities Act of 1933,
as amended (the “Securities Act”), and Section 21E of the
Securities Exchange Act of 1934, as amended (the “Exchange
Act”), which are usually identified by the use of words such as
“anticipates,” “believes,” “estimates,” “expects,” “intends,”
“may,” “plans,” “projects,” “seeks,” “should,” “will,” and
variations of such words or similar expressions. We intend
these forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in
Section 27A of the Securities Act and Section 21E of the
Exchange Act and are making this statement for purposes of
complying with those safe harbor provisions. These
forward-looking statements, including statements relating to
expectations, plans, and prospects regarding our academic
collaboration with Baylor College of Medicine, our ability to
identify and translate cutting-edge research discoveries into
potential therapies for patients with genetic diseases and
genetically driven cancers through our academic collaborations,
the success of current and future relationships with third-party
collaborators and academic partners, and the potential ability
of our product candidates to treat genetically driven diseases
and cancers with clear genetic drivers, reflect our current
views about our plans, intentions, expectations, strategies and
prospects, and are based on the information currently available
to us and on assumptions we have made and are not forecasts,
promises nor guarantees. Although we believe that our plans,
intentions, expectations, strategies and prospects as reflected
in or suggested by these forward-looking statements are
reasonable, we can give no assurance that the plans, intentions,
expectations or strategies will be attained or achieved.
Furthermore, actual results may differ materially from those
described in the forward-looking statements and will be affected
by a number of risks, uncertainties and assumptions, including,
but not limited to, the success of our product candidates to
treat genetically driven diseases and cancers with clear genetic
drivers and the success of our academic collaboration with
Baylor College of Medicine, as well as those risks set forth in
the Risk Factors section of BridgeBio’s most recent Annual
Report on Form 10-K and BridgeBio’s other U.S. Securities and
Exchange Commission filings. Moreover, we operate in a very
competitive and rapidly changing environment in which new risks
emerge from time to time. Except as required by applicable law,
we assume no obligation to update publicly any forward-looking
statements, whether as a result of new information, future
events or otherwise.
BridgeBio Contact:
Grace Rauh
[email protected]
(917) 232-5478
BridgeBio Academic Research Contact:
[email protected]